Pregnancy outcomes after maternal varenicline use; analysis of surveillance data collected by the European Network of Teratology Information Services

Reproductive Toxicology

Volumn 67, Issue , 2017, Pages 26-34

  Richardson, J L ^a,b   Stephens, S ^a,b   Yates, L M ^a,b   Diav Citrin, O ^c   Arnon, J ^c   Beghin, D ^d   Kayser, A ^e   Kennedy, D ^f   Cupitt, D ^f   te Winkel, B ^g   Peltonen, M ^h   Kaplan, Y C ⁱ   Thomas, S H L ^a,b  

^a NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c Israeli Teratology Information Service   (Israel)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f ROYAL HOSPITAL FOR WOMEN   (Australia)

^g Netherlands Pharmacovigilance Centre Lareb   (Netherlands)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ IZMIR KATIP CELEBI UNIVERSITY   (Turkey)

Author keywords

Birth defects; Congenital abnormalities; Elective termination; Intrauterine fetal death; Pregnancy; Smoking cessation; Spontaneous abortion; Varenicline

Indexed keywords

AMFEBUTAMONE; VARENICLINE; NICOTINE GUM; NICOTINIC AGENT;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONGENITAL MALFORMATION; CONTROLLED STUDY; COUNSELING; DATA ANALYSIS; DRUG EFFICACY; DRUG EXPOSURE; DRUG MONITORING; DRUG USE; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MATERNAL WELFARE; NICOTINE REPLACEMENT THERAPY; OBSERVATIONAL STUDY; PREGNANCY OUTCOME; RISK ASSESSMENT; SMOKING CESSATION; CLINICAL TRIAL; CONGENITAL DISORDER; EPIDEMIOLOGICAL MONITORING; EUROPE; MATERNAL EXPOSURE; MULTICENTER STUDY; PREGNANCY; PROSPECTIVE STUDY;

CONGENITAL ABNORMALITIES; EPIDEMIOLOGICAL MONITORING; EUROPE; FEMALE; HUMANS; MATERNAL EXPOSURE; NICOTINIC AGONISTS; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PROSPECTIVE STUDIES; TOBACCO USE CESSATION PRODUCTS; VARENICLINE;

EID: 84995747143     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2016.11.010     Document Type: Article

References (32)

1. [1] Ashford, K.B., Hahn, E., Hall, L., Rayens, M.K., Noland, M., Ferguson, J.E., The effects of prenatal secondhand smoke exposure on preterm birth and neonatal outcomes. J. Obstet. Gynecol. Neonatal. Nurs. 39:5 (2010), 525–535 (PMID: 20919999).
2. [2] Dempsey, D.A., Benowitz, N.L., Risks and benefits of nicotine to aid smoking cessation in pregnancy. Drug Saf. 24:4 (2001), 277–322 (PMID: 11330657).
3. [3] Einarson, A., Riordan, S., Smoking in pregnancy and lactation: a review of risks and cessation strategies. Eur. J. Clin. Pharmacol. 65:4 (2009), 325–330 (PMID: 19169678).
4. [4] Ginzel, K.H., Maritz, G.S., Marks, D.F., Neuberger, M., Pauly, J.R., Polito, J.R., Schulte-Hermann, R., Slotkin, T.A., Critical review: nicotine for the fetus, the infant and the adolescent?. J. Health Psychol. 12:2 (2007), 215–224 (PMID: 17284486).
5. [5] Higgins, S., Smoking in pregnancy. Curr. Opin. Obstet. Gynecol. 14:2 (2002), 145–151 (PMID: 11914691).
6. [6] Marufu, T.C., Ahankari, A., Coleman, T., Lewis, S., Maternal smoking and the risk of still birth: systematic review and meta-analysis. BMC Public Health, 15, 2015, 239 (PMID: 25885887).
7. [7] Matsuda, Y., Hayashi, K., Shiozaki, A., Kawamichi, Y., Satoh, S., Saito, S., Comparison of risk factors for placental abruption and placenta previa: case-cohort study. J. Obstet. Gynaecol. Res. 37:6 (2011), 538–546 (PMID: 21375675).
8. [8] Nicoletti, D., Appel, L.D., Siedersberger Neto, P., Guimaraes, G.W., Zhang, L., Maternal smoking during pregnancy and birth defects in children: a systematic review with meta-analysis. Cad Saude Publica 30:12 (2014), 2491–2529 (PMID: 26247979).
9. [9] Rogers, J.M., Tobacco and pregnancy. Reprod. Toxicol. 28:2 (2009), 152–160 (PMID: 19450949).
10. [10] Rogers, J.M., Tobacco and pregnancy: overview of exposures and effects. Birth Defects Res. C Embryo Today 84:1 (2008), 1–15 (PMID: 18383133).
11. [11] Roskin, J., Aveyard, P., Canadian and English students' beliefs about waterpipe smoking: a qualitative study. BMC Public Health, 9, 2009, 10 (PMID: 19134220).
12. [12] Salmasi, G., Grady, R., Jones, J., McDonald, S.D., Environmental tobacco smoke exposure and perinatal outcomes: a systematic review and meta-analyses. Acta Obstet. Gynecol. Scand. 89:4 (2010), 423–441 (PMID: 20085532).
13. [13] Hartmann-Boyce, J., Stead, L.F., Cahill, K., Lancaster, T., Efficacy of interventions to combat tobacco addiction: cochrane update of 2012 reviews. Addiction 108:10 (2013), 1711–1721 (PMID: 23834141).
14. [14] Coleman, T., Chamberlain, C., Davey, M.A., Cooper, S.E., Leonardi-Bee, J., Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst. Rev., 12, 2015, CD010078 (PMID 26690977).
15. [15] Mihalak, K.B., Carroll, F.I., Luetje, C.W., Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol. Pharmacol. 70:3 (2006), 801–805 (PMID: 16766716).
16. [16] Pfizer Limited. Summary of Product Characteristics − CHAMPIX 0.5 mg film-coated tablets; CHAMPIX 1 mg film-coated tablets (varenicline tartrate). Available from: www.medicines.org.uk/emc/medicine/19045 available at www.webcitation.org/6lXco8m0W (2015).
17. ® (varenicline) Tablets Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2009/021928s012s013lbl.pdf available at www.webcitation.org/6kAVur6hU (2009).
18. [18] Cahill, K., Stevens, S., Perera, R., Lancaster, T., Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst. Rev., 5, 2013, CD009329 (PMID 23728690).
19. [19] De, M., D. Mellon Center for Drug Evauluation and Research Approval Package Pharmacology Review(s) www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021928_s000_Chantix_PharmR.pdf archived at: www.webcitation.org/6dfbSenqe (2006).
20. [20] Kaplan, Y.C., Olgac Dundar, N., Kasap, B., Karadas, B., Pregnancy outcome after varenicline exposure in the first trimester. Case Rep. Obstet. Gynecol., 2014, 2014, 263981 (PMID: 24639907).
21. [21] Harrison-Woolrych, M., Paterson, H., Tan, M., Exposure to the smoking cessation medicine varenicline during pregnancy: a prospective nationwide cohort study. Pharmacoepidemiol. Drug Saf. 22:10 (2013), 1086–1092 (PMID: 23926076).
22. [22] ENTIS. www.entis-org.eu/centers archived at www.webcitation.org/6dHE6Ivby (2016).
23. [23] Schaefer, C., Ornoy, M., Meister, R., Weber-Schoendorfer, C., Using observational cohort data for studying drug effects on pregnancy outcome–methodological considerations. Reprod. Toxicol. 26:1 (2008), 36–41 (PMID: 18588969).
24. [24] Alwan, S., Friedman, J.M., Chapter 25: what is the risk of treating or not treating a pregnant woman with antidepressants?. Hales, B., Scialli, A., Tassinari, M., (eds.) Teratology Primer, 2nd ed., 2010, 67–68.
25. [25] EUROCAT www.eurocat-network.eu/content/EUROCAT-Guide-1.4-Section-3.2pdf archived at www.webcitation.org/6dJ2yNa87 (2013).
26. [26] R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. 2013; Available from: www.R-project.org.
27. [27] Allignol, A., Schumacher, M., Beyersmann, J., Empirical transaction matrix of multi-state models: the etm Package. J. Stat. Softw. 38:4 (2011), 1–15 (PMID: Unlisted).
28. [28] Therneau, T., A package for survival analysis in S. R package version 2, 2013, 37–44.
29. [29] Buhimschi, C.S., Weiner, C.P., Medications in pregnancy and lactation: part 1. Teratol. Obstet. Gynecol. 113:1 (2009), 166–188 (PMID: 19104374).
30. [30] Havard, A., Jorm, L.R., Preen, D., Daube, M., Kemp, A., Einarsdottir, K., Randall, D., Tran, D.T., The Smoking MUMS (Maternal Use of Medications and Safety) Study: protocol for a population-based cohort study using linked administrative data. BMJ Open, 3(9), 2013, e003692 (PMID: 24056492).
31. [31] Pfizer Limited. Varenicline pregnancy cohort study. Details provided at www.clinicaltrials.gov/show/NCT01290445 available at www.webcitation.org/6eMB0nFjC (2016).
32. [32] De Long, N.E., Barra, N.G., Hardy, D.B., Holloway, A.C., Is it safe to use smoking cessation therapeutics during pregnancy?. Expert Opin. Drug Saf. 13:12 (2014), 1721–1731 (PMID: 25330815).